iv bag
Anidulafungin - Eraxis ™
The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgement. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.    PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.

Usual Diluents
D5W, NS

Standard Dilutions   [Amount of drug] [Infusion volume] [Infusion rate]
[50 mg ] [ 100 ml ] [ 1 hour ] (Max rate: 1.1 mg/min)
[ 100 mg ] [ 250 ml ] [ 2 hours ] (Max rate: 1.1 mg/min)
[ 200 mg ] [ 500 ml ] [ 4 hours ] (Max rate: 1.1 mg/min)

Note: each 50 mg vial must be diluted with 15ml (companion diluent) -- see below.

Example: the 200mg dose will contribute 60 ml to the 500ml infusion bag (total volume: 560 ml).

Stability / Miscellaneous
Reconstitution: Aseptically reconstitute each 50 mg vial with 15 mL of the companion diluent (20% (w/w) Dehydrated Alcohol in Water for Injection) to provide a concentration of 3.33 mg/mL. The reconstituted solution should be stored at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). Do not freeze. The reconstituted solution must be further diluted and administered within 24 hours.

DOSAGE AND ADMINISTRATION
Candidemia and other Candida infections (intra-abdominal abscess, and peritonitis)
The recommended dose is a single 200 mg loading dose of ERAXIS on Day 1, followed by 100 mg daily dose thereafter. Duration of treatment should be based on the patient’s clinical response. In general, antifungal therapy should continue for at least 14 days after the last positive culture.

Esophageal candidiasis
The recommended dose is a single 100 mg loading dose of ERAXIS on Day 1, followed by 50 mg daily dose thereafter. Patients should be treated for a minimum of 14 days and for at least 7 days following resolution of symptoms. Duration of treatment should be based on the patient’s clinical response. Because of the risk of relapse of esophageal candidiasis in patients with HIV infections, suppressive antifungal therapy may be considered after a course of treatment.

RENAL DOSING:
Dosage adjustments are not required for patients with any degree of renal insufficiency including those on hemodialysis.

STORAGE
Unreconstituted vials: ERAXIS for Injection unreconstituted vials and companion diluent vials should be stored at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). Do not freeze.

Reconstituted vials: Reconstituted ERAXIS for Injection should be stored at 25°C (77°F); excursions permitted to 15–30°C (59–86°F). Do not freeze. The reconstituted vials must be further diluted and administered within 24 hours.

Aseptically transfer the contents of the reconstituted vial(s) into the appropriately sized IV bag (or bottle) containing either D5W or 0.9% NS.
Dilution requirements for ERAXIS Administration
Dose Number of
50 mg Vials		 Total
Reconstituted
Volume		 Infusion
Volume		 Total
Infusion
Volume		 Infusion
Solution
Concentration
50 mg 1 15 mL 100 mL 115 mL 0.43 mg/mL
100 mg 2 30 mL 250 mL 280 mL 0.36 mg/mL
200 mg 4 60 mL 500 mL 560 mL 0.36 mg/mL

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. If particulate matter or discoloration are identified, discard the solution.

The rate of infusion should not exceed 1.1 mg/minute.

Source: Eraxis [package insert]. New York, NY: Pfizer inc, 2007
The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgement. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material.    PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.